HSV2 vaccine program

  • Therapeutic subunit vaccine
  • T-cell-based
  • Best-in-class antigens by engineering
  • Excellent standing: Redbiotec preclinical vaccine leads show > 90% reduction of lesion score (vs. approx. 50% for GEN-003 of Genocea)
  • Goal: outperform antivirals; symptom-free patients for >12 months upon one time vaccination


  • Three patents on “Means and Methods for Treating HSV“ were filed in March 2016

Potential to increase antigen performance by

  • Optimization of epitope content
  • Evaluation of adjuvant systems
  • Combination of antigens
Download Product Information